Literature DB >> 15969954

Pharmacodynamic comparison of pantoprazole enantiomers: inhibition of acid-related lesions and acid secretion in rats and guinea-pigs.

Hong Cao1, Min-Wei Wang, Li-Xin Sun, Takashi Ikejima, Zhi-Qing Hu, Wei-Hua Zhao.   

Abstract

Pantoprazole is an irreversible proton pump inhibitor that is administered as a racemic mixture clinically. The effects of pantoprazole sodium (PAN.Na) enantiomers on acid-related lesions were compared using models of pylorus ligation induced ulcer, histamine induced ulcer and reflux oesophagitis in rats and guinea-pigs. Compared with (+)-PAN.Na and (+/-)-PAN.Na, (-)-PAN.Na showed much stronger inhibitory effects on pylorus ligation induced and histamine induced ulcers, but similar effects on reflux oesophagitis. The doses of (-)-PAN.Na, (+)-PAN.Na and (+/-)-PAN.Na required for 50% inhibition (ID50) of acid-related lesions were 1.28, 5.03 and 3.40 mg kg(-1) against pylorus ligation induced ulcer, 1.20, 4.28 and 3.15 mg kg(-1) against histamine induced ulcer, and 2.92, 3.56 and 3.70 mg kg(-1) against reflux oesophagitis, respectively. The inhibitory effects of PAN.Na enantiomers on basal gastric acid output were compared in rats with acute fistula. In contrast to inhibitory rates of 89.3% and 83.6% on gastric acid output by (-)-PAN.Na and (+/-)-PAN.Na at 1.5 mg kg(-1), (+)-PAN.Na had an inhibitory rate of only 24.7% at the same dose. The above results indicate that (-)-PAN.Na is more potent than (+)-PAN.Na at inhibiting acid-related lesions owing to its stronger inhibition of acid secretion.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15969954     DOI: 10.1211/0022357056361

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  8 in total

1.  Efficacy of S-pantoprazole 20 mg compared with pantoprazole 40 mg in the treatment of reflux esophagitis: a randomized, double-blind comparative trial.

Authors:  Yu Kyung Cho; Myung-Gyu Choi; Young-Tae Bak; Poong-Lyul Rhee; Sang Gyun Kim; Hoon-Yong Jung; Sang Young Seol
Journal:  Dig Dis Sci       Date:  2012-07-08       Impact factor: 3.199

2.  Safety, pharmacokinetics, and pharmacodynamics of S-(-)-pantoprazole sodium injections after single and multiple intravenous doses in healthy Chinese subjects.

Authors:  Hui-Wen Jiao; Lu-Ning Sun; Yue-Qi Li; Lei Yu; Hong-Wen Zhang; Mei-Feng Wang; Li-Yuan Yu; Zi-Qing-Yun Yuan; Li-Jun Xie; Juan Chen; Ling Meng; Xue-Hui Zhang; Yong-Qing Wang
Journal:  Eur J Clin Pharmacol       Date:  2017-11-22       Impact factor: 2.953

3.  Comparative clinical trial of S-pantoprazole versus racemic pantoprazole in the treatment of gastro-esophageal reflux disease.

Authors:  Vikas G Pai; Nitin V Pai; Hemant P Thacker; Jaisingh K Shinde; Vijay P Mandora; Subhash S Erram
Journal:  World J Gastroenterol       Date:  2006-10-07       Impact factor: 5.742

4.  Is the required therapeutic effect always achieved by racemic switch of proton-pump inhibitors?

Authors:  Quan Zhou; Xiao-Feng Yan; Wen-Sheng Pan; Su Zeng
Journal:  World J Gastroenterol       Date:  2008-04-28       Impact factor: 5.742

5.  Different antiulcer activities of pantoprazole in stress, alcohol and pylorus ligation-induced ulcer models.

Authors:  Dae-Kwon Bae; Dongsun Park; Sun Hee Lee; Goeun Yang; Yun-Hui Yang; Tae Kyun Kim; Young Jin Choi; Jwa Jin Kim; Jeong Hee Jeon; Min-Jung Jang; Ehn-Kyoung Choi; Seock-Yeon Hwang; Yun-Bae Kim
Journal:  Lab Anim Res       Date:  2011-03-25

6.  Anti-Helicobacter pylori effects of IgY from egg york of immunized hens.

Authors:  Yun-Hui Yang; Dongsun Park; Goeun Yang; Sun Hee Lee; Dae Kwon Bae; Jangbeen Kyung; Dajeong Kim; Ehn-Kyoung Choi; Jae-Cheol Son; Seock-Yeon Hwang; Yun-Bae Kim
Journal:  Lab Anim Res       Date:  2012-03-21

7.  Efficacy of S-pantoprazole 10 mg in the Symptom Control of Non-erosive Reflux Disease: A Phase III Placebo-controlled Trial.

Authors:  Yu Kyung Cho; Myung-Gyu Choi; Hyojin Park; Ji Won Kim; Dong Ho Lee; Kwang Hyun Ko; Sang Gyun Kim; Hwoon-Yong Jung; Su Jin Hong; Yong Chan Lee; Si Hyung Lee
Journal:  J Neurogastroenterol Motil       Date:  2021-04-30       Impact factor: 4.924

8.  In vitro and in vivo anti-Helicobacter pylori activities of FEMY-R7 composed of fucoidan and evening primrose extract.

Authors:  Jingmei Cai; Tae-Su Kim; Ja Young Jang; Jihyun Kim; Kyungha Shin; Sung-Pyo Lee; Ehn-Kyoung Choi; Sa-Hyun Kim; Min Park; Jong Bae Kim; Yun-Bae Kim
Journal:  Lab Anim Res       Date:  2014-03-24
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.